ReviewNeuropsychopharmacology reports2022
Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics.
Review in Neuropsychopharmacology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Online training for Japanese healthcare professionals in the development and use of patient decision aids to facilitate shared decision-making: An acceptability study.PEC innovation · 2025Article
- Sleep Aid Effect and Mechanism of Semen Zizyphi Spinosae Extract Enriched With Jujuboside and Jujubogenin in Sleep-Deprived Zebrafish.Food science & nutrition · 2025Article
- Effects of happy sensation training group on the symptom of anxiety, depression and sleep structure: a randomized controlled trial.Frontiers in neuroscience · 2025Article
- Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia.Neuropsychopharmacology reports · 2023Article
- A Comparison between Perceptions of Psychiatric Outpatients and Psychiatrists Regarding Benzodiazepine Use and Decision Making for Its Discontinuation: A Cross-Sectional Survey in Japan.International journal of environmental research and public health · 2023Article
- Development and acceptability of a decision aid for anxiety disorder considering discontinuation of benzodiazepine anxiolytic.Frontiers in psychiatry · 2023Article
- Decision aid development and its acceptability among adults with attention-deficit/hyperactivity disorders regarding treatment discontinuation after remission.PCN reports : psychiatry and clinical neurosciences · 2022Article
- Attitudes and Difficulties Associated with Benzodiazepine Discontinuation.International journal of environmental research and public health · 2022Article
- Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission.Neuropsychopharmacology reports · 2022Article
- Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics.Neuropsychopharmacology reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo describe the development and acceptability of a decision aid (DA) for chronic insomnia considering discontinuation of benzodiazepine (BZD) and benzodiazepine receptor agonist (BZRA) hypnotics, and if discontinuing, tapering with or without cognitive behavioral therapy for insomnia (CBT-I).
methodsWe reviewed relevant literature describing chronic insomnia to identify options. We used the results of the systematic review and meta-analysis conducted previously to determine the related outcomes of two options: discontinuation of BZD/BZRA hypnotics by gradual tapering alone and discontinuation of BZD/BZRA hypnotics by gradual tapering with CBT-I. We then developed a prototype of DA following the International Patient Decision Aid Standards. A mixed methods survey was conducted to assess the acceptability among patients and healthcare providers.
resultsThe prototype consisted of a description of insomnia, options of continuing or discontinuing BZD/BRZA hypnotics (if discontinuing, the options of tapering hypnotics with or without CBT-I), pros and cons of each option, and a value clarification exercise. Patients (n = 24) reported that the DA had acceptable language (79%), adequate information (71%), and well-balanced presentation (91%). Healthcare providers (n = 20) also provided favorable feedback.
conclusionWe developed a DA for chronic insomnia considering discontinuation of BZD/BRZA hypnotics, which was acceptable for stakeholders. The developed DA was designed to support patients and healthcare providers to make a decision about whether to discontinue BZD/BRZA hypnotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.